A FPA008 trial in 12 rheumatoid arthritis patients and a phase 1 study of ARRY-382 in cancer patients have been reported as meeting abstracts and show that CSF1R inhibition leads to increased serum CSF1 and/or IL-34 levels and diminished NTX228,229. Here, CSF1R is linked to cancer.